ArticleBiomarker research2013
Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapy.
Article in Biomarker research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Meta-analysis of gene expression profiles identifies differential biomarkers for hepatocellular carcinoma and cholangiocarcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Pooled it
- Evaluating the role of preoperative serum insulin-like growth factor 1 as a predictor of survival and recurrence for patients with resectable hepatocellular carcinoma.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2026Article
- Revolutionizing early HCC detection: groundbreaking validation of the HCC-check index for small tumors in Egyptian patients using CLIP and BCLC staging systems.Medical oncology (Northwood, London, England) · 2025Article
- Yang-deficiency constitution drives poor outcomes in clear cell renal cell carcinoma by modulating the tumour immune microenvironment.Frontiers in immunology · 2025Article
- Towards precision medicine: design considerations for nanozymes in tumor treatment.Journal of translational medicine · 2024Review
- Discovering novel prognostic biomarkers of hepatocellular carcinoma using eXplainable Artificial Intelligence.Expert systems with applications · 2024Article
- Metabolomics Biomarker Discovery to Optimize Hepatocellular Carcinoma Diagnosis: Methodology Integrating AutoML and Explainable Artificial Intelligence.Diagnostics (Basel, Switzerland) · 2024Article
- Serum Levels of Netrin-4 and Its Association With Hepatocellular Carcinoma: Results From a Case-Control Study.Cureus · 2023Article
- Assessment of serum CXCL9 and pentraxin 3 as novel markers for hepatocellular carcinoma in cirrhotic hepatitis C patients.Clinical and experimental hepatology · 2023Article
- Gadoxetic Acid-Enhanced MRI-Based Radiomics Signature: A Potential Imaging Biomarker for Identifying Cytokeratin 19-Positive Hepatocellular Carcinoma.Computational and mathematical methods in medicine · 2023Article
- Field cancerization profile-based prognosis signatures lead to more robust risk evaluation in hepatocellular carcinoma.iScience · 2022Article
- Review
- RNA-seq profiling reveals PBMC RNA as a potential biomarker for hepatocellular carcinoma.Scientific reports · 2021Article
- Matrix Metalloproteinase-11 Gene Polymorphisms as a Risk for Hepatocellular Carcinoma Development in Egyptian Patients.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Clinical Significance of Annexin A4 as a Biomarker in the Early Diagnosis of Hepatocellular Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Plasma hsa_circ_0027089 is a diagnostic biomarker for hepatitis B virus-related hepatocellular carcinoma.Carcinogenesis · 2020Article
- Identification of Long Noncoding RNA Biomarkers for Hepatocellular Carcinoma Using Single-Sample Networks.BioMed research international · 2020Article
- Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma.BMC cancer · 2019Article
- Circulating-Free DNA Analysis in Hepatocellular Carcinoma: A Promising Strategy to Improve Patients' Management and Therapy Outcomes.International journal of molecular sciences · 2019Review
- microRNA-17 functions as an oncogene by downregulating Smad3 expression in hepatocellular carcinoma.Cell death & disease · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world. Currently, surgical resection, liver transplantation, and local ablation are considered curative therapeutic practices for HCC. The diagnosis of HCC without pathologic confirmation is achieved by analyzing serum alpha-fetoprotein (AFP) levels combined with imaging techniques, including ultrasonography, magnetic resonance imaging, and computerized tomography. Although progress has been made in the diagnosis and management of HCC, its prognosis remains dismal. Various new technologies have identified numerous novel biomarkers with potential diagnostic as well as prognostic value, including Dickkopf-1 and Golgi protein 73. These biomarkers not only help in the early diagnosis and prediction of prognosis, but also assist in identifying potential targets for therapeutic interventions. In this article, we provide an up-to-date review of the biomarkers that are used for early diagnosis, prognosis prediction, and personalized treatment of HCC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.